EMILY MOORE: Open Payments
NPI 1871001412 · DECATUR, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,901 in 85 payments from 24 companies in 2025. Trend: 2023 $2,042 · 2024 $2,554 · 2025 $1,901
Food & beverage: $1,901
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $383 |
| Neurocrine BioSciences, Inc. | 6 | $148 |
| Alexion Pharmaceuticals, Inc. | 5 | $144 |
| Merz Pharmaceuticals, LLC | 4 | $113 |
| Biogen, Inc. | 5 | $108 |
| CATALYST PHARMACEUTICALS, INC. | 4 | $106 |
| Eisai Inc. | 3 | $102 |
| SK Life Science, Inc. | 5 | $96 |
| Axsome Therapeutics, Inc. | 3 | $81 |
| Neurelis, Inc. | 4 | $71 |
Products named: BOTOX, LEQEMBI, INGREZZA, ULTOMIRIS, Xeomin, FYCOMPA, QULIPTA, REXULTI.
Industry payments across AL — which companies pay providers there.
